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Background/aim: Gemcitabine, dexamethasone and cisplatin (GDP) is a well-established salvage regimen for relapsed and refractory
lymphomas. In this study, we aimed to share our experience with the patients who received GDP/R-GDP (rituximab-gemcitabine,
dexamethasone and cisplatin) for stem cell mobilization.
Materials and methods: Data of 69 relapsed and refractory Hodgkin lymphoma (HL) and Non-Hodgkin lymphoma (NHL) patients
who received GDP/R-GDP as salvage chemotherapy in our center between July 2014 and January 2020 were retrospectively evaluated.
After the evaluation of response, 52 patients had a chemosensitive disease and underwent mobilization with GDP/R-GDP plus G–CSF
(granulocyte colony-stimulating factor). Collected CD34+ stem cells and related parameters were compared in terms of diagnosis of
HL and NHL, early and late stage, patients who did not receive RT and those who received RT, and patients aged under 60 and over 60.
Results: On the 15th day on average (range 11–20), a median number of 8.7 × 106 /kg (4.1–41.5) CD34+ stem cells were collected
in 51 (98%) of our 52 chemosensitive patients and 1 (2%) patients failed to mobilize. We observed acceptable hematological and
nonhematological toxicity. The targeted amount of 2 × 106 /kg CD34+ stem cells was attained by 98% (n: 51) patients, and all of them
underwent autologous stem cell transplantation. Moreover, low toxicity profiles provide outpatient utilization option clinics with close
follow-up and adequate supportive care.
Conclusion: We suggest that GDP/R-GDP plus G-CSF can be used as an effective chemotherapy regimen for mobilizing CD34+ stem
cells from peripheral blood in relapsed and refractory lymphoma patients due to low toxicity, effective tumor reduction, and successful
stem cell mobilization. It can also be assumed that the GDP mobilization regimen may be more effective, especially in patients with
early-stage disease and in HL patients.
Key words: Gemcitabine, dexamethasone, cisplatin, stem cell mobilization, relapsed and refractory lymphoma

1. Introduction
Autologous stem cell transplantation (ASCT), which is a
highly therapeutic approach to the treatment of relapsed
and refractory lymphoma, is extremely dependent on the
mobilization and collection of hematopoietic stem cells
(HSC) [1,2]. HSCs can be collected directly from the bone
marrow or peripheral blood (PB) by apheresis. ASCTs
are performed primarily with peripheral blood stem
cells (PBSC). The release of HSCs to PB after granulocyte
colony-stimulating factor (G-CSF) treatment and/or
chemotherapy is known as mobilization. CD34+ cells do
not exceed 0.05% of white blood cells (WBCs) under

normal conditions in PB. After combining chemotherapy
and G-CSF, the number of PBSC increases from 5 to 15
times [3–5].
The target quantity of HSC to be collected is dependent
on the underlying disease (Non-Hodgkin lymphoma
(NHL), Hodgkin lymphoma (HL), and the number of
transplants. The minimum dose considered to be safe in case
of ASCT is 2 × 106 CD34+ cells/kg per transplant; however,
the aim of many centers is higher yields of 4–5 × 106 CD34+
cells/kg as it may allow faster neutrophil and platelet (PLT)
recovery, reduced hospitalization, blood transfusions, and
antibiotic therapy. The ideal dose required for successful
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transplantation was considered to be 5 × 106 CD34+ cells/
kg [6–8]. The choice of a specific chemomobilization
approach is based on the patient’s disease characteristics
and local clinical practice guidelines. The applications that
incorporate both the G-CSF and chemotherapy regimens
were shown to mobilize more PBSCs than G-CSF alone
[9,10].
The combination of G-CSF and chemotherapy is
favored for stem cell mobilization and for tumor burden
reduction and especially those who need to harvest
a greater count of stem cells. It is an option to utilize
mobilization not by splitting chemotherapy apart, however,
through more precise, disease definite chemotherapy
regimens such as; rituximab dexamethasone cytarabine
cisplatin (R-DHAP) or rituximab, ifosfamide, carboplatin,
and etoposide (R-ICE) for lymphoma patients [11]. After
chemotherapy regimen employment, G-CSF daily dosage
for mobilization was recommended as filgrastim 10 μg/kg
and lenograstim 150 μg/m2. The G-CSF should be initiated
following the fulfillment of chemotherapy instantly when
leukocyte nadir is detected, and it should be continued till
the ending of leukapheresis. Generally, it is recommended
to begin G-CSF in 1–5 days following the completion
of chemotherapy. Nonetheless, chemomobilization
is not a panacea and has some detrimental aspects
such as; therapy-associated toxicity, need for frequent
hospitalization, harming bone marrow for forthcoming
mobilizations and huge cost [11]. Also, it is known that
repeated interventions for mobilization after failures
constitute a burden for resource utilization and morbidity
[12]. Considering all these factors together, determination
of the most appropriate chemotherapy regimen for
mobilization gains more importance [13].
The data regarding gemcitabine, dexamethasone, and
cisplatin (GDP)/rituximab, gemcitabine, dexamethasone,
and cisplatin (R-GDP) on stem cell mobilization are not
widely investigated. This study is particularly designed
to determine the results of GDP/R-GDP regimen plus
G-CSF on mobilization as salvage therapy in patients with
relapsed and refractory lymphoma.
2. Materials and methods
Data of 69 relapsed and refractory HL and NHL patients
who received GDP/R-GDP as salvage chemotherapy
in our center between July 2014 and January 2020 were
retrospectively evaluated. All the patients received GDP/
R-GDP as salvage regimen (rituximab 375 mg/m2 on day
0, gemcitabine 1000 mg/m2 on days 1 and 8, cisplatin 75
mg/m2 on day 1, dexamethasone 40 mg/day on days 1,
2, 3 and 4: standard doses without dose modifications).
Response assessment was based on imaging results from
fluorodeoxyglucose–positron emission tomographycomputed tomography (FDG/PET-CT) and computed
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tomography (CT) scans after treatments. The FDG/PET–
CT and CT scans were evaluated by using Lugano criteria
to assess FDG/PET–CT in lymphoma response criteria
published in 2014 [14]. Fifty-two patients who received
GDP/R-GDP had a chemosensitive disease. After GDP was
given, it was the nadir for neutrophil to decrease and start
to increase again, and G-CSF (2 × 5 g/kg/day) was started.
Stem cell mobilization practice for lymphoma patients
in our center was to start apheresis when the peripheral
blood CD34+ count (PB CD34+) was > 10 cells/L, with a
collection target of > 5 × 106 CD34+ cells/kg. Mobilization
failure was defined as achieving a total CD34+ yield of < 2
× 106 cells/kg. Stem cell mobilization with GDP/R–GDP
was compared in terms of diagnosis of HL and NHL, early
and late stage, patients who did not receive RT and those
who received RT, and patients under 60 and over 60 years
of age.
2.1. Statistical analysis
The SPSS version 21.0 (IBM Corporation, Armonk, NY,
USA) was applied to analyses. The categorical variables
were presented as frequency tables, and the numerical
variables were presented as either mean ± standard
deviations or median and minimum-maximum values,
where appropriate. Distributions of continuous variables
were assessed with graphics and Kolmogorov–Smirnov
test. Mann–Whitney U test was implemented to compare
the nonparametric continuous variables within the
groups. A chi-square test was used to analyze apheresis
count frequency between the groups. A P-value ≤ 0.05 was
regarded as statistically significant.
3. Results
GDP/R–GDP was given to 69 relapsed and refractory
HL and NHL patients as salvage chemotherapy. Of the
patients, 42 (60.9%) were males, and 27 (39.1%) were
females. 38 (55%) patients had the diagnosis of HL, and
31 (45%) patients had NHL. The mean age of the patients
was 43.9 ± 15.2 years. The demographic and clinical
characteristics of the patients are summarized in Tables 1
and 2. After the evaluation of response to GDP or R-GDP
regimen, a mobilization with G-CSF was performed for 52
patients who had a chemosensitive disease. On the 15th
day, on average (range 11–20), ____ CD34+ stem cells
were collected. The G-CSF mean was performed for 5 days
(range 3–11). Peripheral CD34+ stem cell count before
collection (on the day of collection) was between 11 and
467 cells?/μL, and median number of peak CD34+ stem
cells in peripheral blood was 55 cells?/μL. The CD34+ stem
cells were collected in 51 of our 52 chemosensitive patients
(≈ 98%), and 1 (≈ 2%) patients failed to mobilize. In 51
patients, > 2 × 106 CD34+ stem cells/kg (median 8.68 × 106,
range 4.06–41.50) were successfully collected. They were
collected with one leukapheresis procedure in 34 patients,
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Table 1. Demographic and clinical characteristics of the patients.
Diagnosis

HL (n: 38); NHL (n: 31)
17–77 years (range) (mean
Age
age: 43.9)
Sex
Male (n:42); Female (n:27)
Relapse (n:40); Refractory
Disease status
(n:29)
Radiotherapy
Yes (n:14); no. (n:55)
1 line (n: 60); 2 line (n: 7); 3
Previous number of chemoline (n: 1); 4
therapies
line (n: 1)
GDP/R-GDP
GDP (n:42); R-GDP (n: 27)
Ann Arbor stage before GDP/ Stage 1 (n: 4); Stage 2 (n: 13);
R-GDP treatment
Stage 3(n: 16); Stage 4 (n: 36)
Bone marrow involvement
3/38 (8%); 8/31 (25.8%)
GDP/R-GDP number of
2 (n: 36); 3 (n: 26); 4 (n: 7)
cycles
GDP/R-GDP treatment reChemorefractory disease n: 17;
sponse
Chemosensitive disease n: 52
n: 52
(n: 51,
98%
Stem cell mobilization with
successful;
n: 1,
GDP/R-GDP
2% unsuccessful)

HL; Hodgkin’s lymphoma, NHL; Non-Hodgkin’s lymphoma.

Table 2. Clinical characteristics of patients.
Clinical characteristics
Lymphoma type
Hodgkin’s lymphoma
Non-Hodgkin’s lymphoma
Diffuse large B-cell lymphoma
T-cell lymphoma
Mantle cell lymphoma
Follicular lymphoma
Marginal zone lymphoma
Previous chemotherapies
Hodgkin’s lymphoma
ABVD
ABVD + radiotherapy
Non-Hodgkin’s lymphoma
R-CHOP
R-CHOP + radiotherapy
CHOP
R-EPOCH
CHOEP

Number of patients (n)
69
38
31
24
4
1
1
1

27
11
21
3
4
2
1

ABVD; adriamycin, bleomycin, vinblastine, dacarbazine, R-CHOP;
rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone, CHOP; cyclophosphamide, doxorubicin, vincristine, and
prednisone, R-EPOCH; rituximab, etoposide, prednisone, vincristine,
cyclophosphamide,
doxorubicin,
CHOEP;
cyclophosphamide,
daunorubicin, vincristine, etoposide, prednisone.

with two leukapheresis procedures in 15 patients, and with
three leukapheresis procedures in 2 patients. The results of
PBPCs collection are summarized in Table 3.
Demographic and clinical characteristics of the patients
with successful mobilization are summarized in Table 4.
The mean age of the patients with successful mobilization
(n: 51) was 44 ± 14.5 years. Twenty-nine (≈ 57%) were
males and 22 (≈ 43%) were females. Twenty-four (≈ 47%)
patients had the diagnosis of HL, and 27 (≈ 53%) patients

Table 3. Results of peripheral blood stem cells collection.
Variable
Median CD34+ cell count in
peripheral blood (/μL) (range)
Median apheresis days (range)
Leukapheresis procedure count
(n)
Median total CD34+ cells collected (106/kg) (range)
Out of target (< 2 × 106 CD34
+ cells/kg) (%)
Above minimum target (>
2×106 CD34 + cells/kg) (%)
Above optimal target (> 5×106
CD34 + cells/kg) (%)

All patients, n: 52
55.04 (11.07–467.18)
15 (11–20)
1 (n: 34); 2 (n: 15); 3 (n: 2)
8.68 (4.06–41.50)
1 (2)
51 (98)
48 (92)

Data are presented as number (n or %) or median (minimummaximum), where appropriate.

Table 4. Demographic and clinical characteristics of successfully
mobilized patients.
Variable

All patients, n: 51

Median age (range)

44 (18–77)

Sex

Male (n: 29); Female (n: 22)

Diagnosis

HL (n: 24); NHL (n: 27)
Relapse (n: 22); Refractory
(n: 29)
15

Disease status
Stage 1–2, n
Stage 3–4, n
Patients undergoing radiotherapy, n
Median CD34 cell count in
peripheral blood (cells?/μL)
(range)
Previous line of chemotherapy

36
11
55.04 (11.07–467.18)
1 line (n: 45); 2 line (n: 4); 3
line (n: 1); 4 line (n: 1)

Data are presented as number (n) or median (minimummaximum), where appropriate.
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had NHL. Of these, 22 were relapsed, 29 were refractory,
and 15 had early stage and 36 had an advanced stage
disease. The patient with unsuccessful mobilization was a
25-year-old female relapse Stage 3BX HL who had received
one-line chemotherapy before and had a history of RT. Her
response to GDP was a complete response. After nearly 3
weeks, CD34+ stem cells were collected with a G-CSF plus
plerixafor.
Blood parameters at the collection date are shown in
Table 5. The PLT count was below 150 × 109 /L in 42 (82%)
of 51 patients and below 100 × 109 /L in 34 (67%) of 51
patients. 2 patients (4%) had neutropenia (< 1.500 × 109
/L).
Grade 1–2 toxicity was approximately 5.9% (n: 3),
which was ototoxicity, mucositis, and/or nephrotoxicity.
Grade 3–4 toxicity was approximately 7.8% (n: 4),
which was neutropenia (n: 2), febrile neutropenia (n:
1), infections requiring hospital admission (n: 2) and/or
nephrotoxicity (n: 1).
Patients under 60 years of age had a higher number of
CD34+ stem cells collected on day 1 than those over 60
years of age (P: 0.03). However, there was no difference
in total CD34+ collected. The amount of premobilization
PLT, apheresis day PB CD34+, CD34+ on the first day, and
Table 5. Blood parameters at harvest.
Variable

Leukocyte count (×109/L)
Hemoglobin level (g/dL)
Platelet count (×109/L)

Neutrophil count (×109/L)

Median (range)
14 (2.44–53.6)
11.2 (7.57–13.4)
62 (20–181)
8.7 (1.05–42.74)

CD34+ total in HL patients were higher than in the NHL
patients (P: 0.02, P: 0.002, P: 0.006, P: 0.03, respectively).
In the early-stage patients, total CD34+ amount, and
apheresis day PB CD34+ was found higher than in the
late-stage patients (P: 0.02 and P: 0.04, respectively). As
shown in Tables 6 and 7, when patients who received
RT were compared with those who did not receive RT,
no statistically significant difference was found in terms
of WBC, PLT, and premobilization PB CD34+ stem cell
counts, total number of collected CD34+ stem cells,
number of CD34+ stem cells collected on the 1st day, and
apheresis procedures.
4. Discussion
Currently, the number of 2 × 106 CD34+ cells/kg is generally
considered to be the minimum stem cell count needed for
a successful ASCT. Ideally, the optimum value is generally
considered to be > 5 × 106 CD34+ cells/kg, and the sum
of collected stem cells below < 2 × 106 CD34+ cells/kg is
regarded as mobilization failure [6,7,8,15].
Various chemotherapeutic agents are used in
conjunction with G-CSF for stem cell mobilization in ASCT.
Chemotherapeutic agents should be both effective against
the underlying disease and should also facilitate stem cell
mobilization; thus, both cytoreduction and mobilization
should be provided together. This is the reason why single
agents such as cyclophosphamide, etoposide, cytarabine,
etc. are used along with G-CSF for both pretransplant
cytoreduction and stem cell mobilization; therefore,
combined regimens such as GDP, cisplatin, cytosine
arabinoside and dexamethasone (DHAP), doxorubicin,
methylprednisolone, high-dose cytarabine and cisplatin

Table 6. Relationship of mobilization and laboratory parameters with clinical variables.
Age
Median (min-max)
WBC
PLT
PB CD34
CD34 (1st)
CD34 (T)
Apheresis
count

Diagnosis

Aged < 60 (n: 39)

Aged ≥ 60 (n: 12) P value

13.7
(2.4–53.6)
65.5
(20–181)
73.6
(11.1–467.2)
6.5
(2.3–41.5)
9.5
(4.1–41.5)
1
(1–3)

14
(6.6–34.1)
52
(20–107)
35.2
(19.5–213)
3.6
(1.7–20)
8.2
(5.5–20)
2
(1–3)

0.85
0.51
0.12
0.03*
0.31
0.12

HL (n: 24)

NHL (n: 27)

15.7
(3.2–53.6)
73
(30–134)
119.3
(19.5–467.2)
11.5
(2.2-34.3)
12.4
(4.7–34.3)
1
(1–2)

10.1
(2.4–46.2)
46
(20–181)
35.2
(11.1–173.8)
4.3
(1.7–41.5)
8.3
(4.1–41.5)
2
(1–3)

P value
0.12
0.02*
0.002*
0.006*
0.03*
0.11

WBC; white blood cells, PLT; platelet, PB; peripheral blood, CD34 (1st); first day collected stem cell amount, CD34 (T); total collected
stem cell amount.
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Table 7. Relationship of mobilization and laboratory parameters with clinical variables.
Stage
Median
(min-max)
WBC
PLT
PB CD34
CD34 (1st)
CD34 (T)
Apheresis
count

Early
(n: 15)
17.6
(3.2–53.6)
74
(24–134)
106.7
(33.1–337.6)
10.6
(3.3–20)
12.5
(4.1–20)
1
(1–2)

Late
(n: 36)
12.5
(2.4–46.2)
52
(20–181)
36.8
(11.1–467.2)
4.9
(1.7–41.5)
8.3
(4.7–41.5)
1
(1–3)

P value
0.19
0.10
0.02*
0.09
0.04*
0.33

RT
RT
(n:11)
14.7
(6.6–34.9)
97
(36-123)
132.5
(29.3–399.1)
6.5
(2.0–13.3)
9.5
(4.7–17.1)
1
(1–2)

Non-RT
(n:40)
12.5
(2.4–53.6)
55
(20-181)
50.68
(11.1–467.2)
5.95
(1.7–41.5)
9.14
(4.1–41.5)
1
(1–3)

P value
0.33
0.15
0.90
0.98
0.92
0.71

WBC; white blood cells, PLT; platelet, PB; peripheral blood, CD34 (1st); first day collected stem cell amount, CD34 (T); total collected
stem cell amount.

(ASHAP), Vinorelbine, gemcitabine, procarbazine and
prednisone (ViGePP) and ifosfamide, carboplatin, and
etoposide phosphate (ICE) have been used as stem cell
mobilizing regimens in hematology units [16–18]. By
using salvage chemotherapy in patients with relapsed or
refractory HL, failure of 3%, 18%, and 14% mobilization
rates were reported for GDP, carmustine cytarabine
etoposide melphalan (Mini-BEAM), and ICE, respectively
[16,17].
Bozdağ et al. investigated the effect of chemotherapy
regimens on mobilization in lymphoma patients [18].
Patients were given chemotherapy protocols such as
cyclophosphamide (n: 15), ASHAP (n: 11), and ViGePP
(n: 12) [18]. Although no difference was reported
between the groups concerning the number of stem cells
collected (P: 0.58), mobilization failure was 33% in the
cyclophosphamide group (n: 5/15), 9% in the ASHAP
group (n: 1/11) and 8% in the ViGePP group (n: 1/12) [18].
Berber et al. evaluated the effectiveness of the DHAP
regimen plus filgrastim for mobilization of stem cells in
relapsed and/or refractory lymphoma patients [19]. Stem
cells from 32 patients (94%) were collected on the 11th day
on average and the median CD34+ cell count collected was
9.7 × 106 /kg (range 3.8–41.6) [19]. Mobilization failure
in salvage treatments was reported as 10% in diffuse large
B-cell lymphoma (DLBCL) (n: 197) patients given R-ICE,
and it was 8% in DLBCL (n: 191) patients given R-DHAP
[20]. Moccia et al. provided GDP salvage treatment to
235 relapsed and refractory HL and NHL patients in
their study [21]. Autologous stem cell transplantation was
applied to 126 patients (69 HL and 57 DLBCL) in total
[21]. In addition, Moccia AA et al. also reported GDP as
an effective out-patient salvage regimen for relapsed and

refractory DLBCL and HL. However, in the study, the
effectiveness of GDP on PBSC mobilization has not been
adequately evaluated [21].
In the current study, we evaluated the efficacy of the
GDP/R-GDP regimen plus G-CSF to mobilize PBSCs in
relapsed and refractory lymphoma patients. Successful
mobilization was achieved in 51 of chemosensitive
patients and approximately 98% of patients had stem cells
collected over 2 × 106 cells?/kg. Our mobilization failure
was nearly 2%, and our mobilization failure seemed to be
lower when compared to the reports of Mini-BEAM, ICE,
cyclophosphamide, ASHAP, ViGePP, R-ICE, and R-DHAP
regimens usage reported previously [15–18]. Besides,
our study suggests that GDP mobilization regimen may
be more effective in HL patients in comparison to NHL
patients in terms of premobilization PLT levels, PB CD34+
stem cell counts, first-day collected stem cell amount of the
mobilization, and the total number of CD34+ stem cells
collected as shown in Tables 6 and 7.
Plerixafor could be added to G-CSF at a dose of 24 µg/
kg when there is a possibility of inadequate mobilization
(defined as PB CD34+ stem cell number < 10 cells/L on
the first apheresis day planned or target CD34+ stem
cell yield on the first day of apheresis < 50%) [23,24].
Tang C et al. used 4% and 18% plerixafor in regimens
(CE (cyclophosphamide/etoposide) + G-CSF and GDP
+ G-CSF), respectively [24]. Besides, they reported
the mobilization failure as 1.2% [24]. In our study,
mobilization failure was 2% and only 1 patient used G-CSF
plus plerixafor. Eventually, GDP regimen seemed not to
need very high rates of plerixafor usage.
Patient and disease-related factors predicting
mobilization failure are being over 60 years of age, having
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an underlying advanced disease, having previously
received more than one-line chemotherapy, and having
low CD34+ cells in peripheral blood before apheresis.
However, the low PLT count before mobilization and
previous treatments, including fludarabine, melphalan,
or lenalidomide are controversial factors in terms of
mobilization failure. It is generally accepted that the most
influential predictive factor for mobilization failure is the
number of CD34+ cells in preapheresis PB [6].
From a total of 145 patients, 52% of whom were
diagnosed with lymphoma, participated in a study
conducted by Demiriz et al. [25]. The patients were divided
into two groups according to successful and unsuccessful
mobilization and the groups were compared in terms of the
parameters affecting the mobilization success [25]. Among
the factors of age, platelet count, LDH, ferritin, CRP, LDL,
and triglyceride levels, it was only high platelet count that
was shown to be effective in mobilization success in their
study (P < 0.05) [25]. On the other hand, due to the high
platelet count before mobilization, the number of stem
cells collected in HL patients was found to be higher than
in NHL patients in this study and it would be an indicator
of bone marrow reserve.
Dogu MH et al. showed that age, the number of
chemotherapy cycles taken before mobilization, and
radiation therapy had no significant effect on the number
of final CD34+ stem cell yield (P: 0.492, 0.746, and 0.078,
respectively) [26]. On the contrary, in our study, the
amounts of CD34+ stem cells collected on the 1st day in
patients under 60 years of age and older than that were
different; however, total amounts of collected CD34+
stem cells were similar. However, there was no difference
in terms of the amount of collected total CD34+ between
the patients who received RT and those who did not. In
addition, when early stage patients were compared with
late stage patients, the total number of collected CD34+
stem cells was found to be significantly higher in the early
stage patients.

Tang C et al. examined the efficacy and safety of PBSC
mobilization following CE + G-CSF versus GDP + G-CSF
[24]. Patients mobilized with CE + G-CSF required fewer
days of leukapheresis (median 1 vs. 2 days; P: 0.001)
and achieved a higher total CD34+ stem cell yield than
patients mobilized with GDP + G-CSF (8.5 × 106 vs. 7.1
× 106 CD34+ cells/kg; P: 0.001) [24]. Frequencies of febrile
neutropenia and rates of CD34+ stem cell collection ≥ 5 ×
106 CD34+ cells/kg were similar [24]. Furthermore, in our
study, GDP/R-GDP regimens provided a median number
of 8.68 × 106 cells?/kg of CD34+ stem cells (range 4.06–
41.50) PBSCs. Total CD34+ stem cell yield was collected
by one leukapheresis procedure in 34 (≈ 66.7%) patients,
2 leukapheresis procedures in 15 patients (≈ 29.4%), and 3
leukapheresis procedures in 2 (≈ 3.9%) patients.
In conclusion, we observed acceptable hematological
and nonhematological toxicities with R-GDP/GDP salvage
chemotherapies used in relapsed and refractory lymphoma
patients. We also showed high rates of successful stem cell
mobilization in relapsed and refractory lymphoma patients
receiving GDP/R-GDP salvage chemotherapies. Therefore,
GDP/R-GDP chemotherapy regimens should also be
kept in mind as an alternative for salvage chemotherapy
followed by peripheral stem cell mobilization in patients
with relapsed and refractory lymphoma. It can also be
assumed that a GDP mobilization regimen may be more
effective, especially in patients with early-stage disease and
also HL patients.
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